-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In patients who discontinued denosumab (DMAB), bone turnover increased rapidly, and the increased bone mass was lost over 12 to 24 months over the course of treatment
.
DMAB is a fully human IgG2 monoclonal antibody that neutralizes the receptor activator of nuclear factor kappa-B ligand (RANKL)
.
We investigated the long-term efficacy of zoledronate (ZOL) in maintaining bone mineral density (BMD) after discontinuation of denosumab
.
In this randomized, open-label interventional study, we included 61 postmenopausal women and men over 50 years of age who discontinued denosumab after 4.
6±1.
After discontinuing long-term DMAB, some ZOL patients were treated with three different regimens and re-treated in the first year, and their BMD was maintained within the premenopausal reference interval in the second year, and CTX was stable within the premenopausal reference interval
.
After 24 months of treatment, the mean bone loss in the spine was 4.
2% and the mean bone loss in the total hip was 3.
Source: Sølling AS, Harsløf T, Langdahl B, Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study, J Bone Miner Res 2021 Jul;36(7)
Sølling AS, Harsløf T, Langdahl B, Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study, J Bone Miner Res 2021 Jul;36(7)
leave a message here